The top 5 OncLive TV videos of the week cover insights in ovarian cancer, breast cancer, head and neck cancer, pancreatic cancer, and follicular lymphoma.
News|Articles|September 3, 2026
Novel Therapies Are Poised to Answer Questions and Reinvigorate Hematologic Oncology at SOHO 2026
Author(s)Chris Ryan, Riley Kandel
Fact checked by: Chris Ryan, Riley Kandel
Experts break down SOHO 2026 and topics at the meeting that will shape hematologic oncology for the rest of the year.
Advertisement
Advertisement
The
Related to this article
Etentamig improved ORR and PFS vs standard therapies in triple-class exposed relapsed/refractory multiple myeloma.
Uma Borate, MBBS, MS, discusses data for different azacitidine and venetoclax schedules from the Beat AML master clinical trial.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
Faculty convened at an OncLive Scientific Interchange and Workshop to weigh how new regimens should reshape sequencing in prostate cancer.
MT027, an off-the-shelf B7-H3–directed CAR T-cell therapy, earned FDA fast track designation for recurrent glioblastoma.
During a recent OncLive Peer Exchange, panelists discussed testing strategies, updated data, and treatment sequencing in ROS1+ NSCLC.
The MAPKeeper-301 trial is evaluating frontline atebimetinib plus chemotherapy vs standard chemotherapy in metastatic pancreatic ductal adenocarcinoma.
Advertisement
Advertisement